The Valens Company Inc. (VLNS) Stock Analysis
DELISTED 2023
What happened to The Valens Company Inc. (VLNS) stock?
The Valens Company Inc. (VLNS) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
The Valens Company Inc. (VLNS) trades at $0.7612. The Valens Company Inc. is a Canadian-based developer, manufacturer, and seller of cannabinoid-based products, operating both domestically and internationally. Market cap: $61.5M, Sector: Healthcare.
Last analyzed: Mar 18, 2026Analyst Coverage for VLNS: VLNS does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VLNS against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
VLNS: 1/2 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →The Valens Company Inc. (VLNS) Healthcare & Pipeline Overview
The Valens Company Inc. is a Canadian developer, manufacturer, and seller of cannabinoid-based products, offering a wide array of cannabis and hemp products, extraction, and manufacturing services. Operating in Canada and internationally, Valens focuses on product innovation and custom manufacturing within the specialty and generic drug manufacturing sector.
What Is the Investment Thesis for VLNS?
The Valens Company Inc. presents a speculative investment opportunity within the cannabis sector, contingent on its ability to achieve profitability and navigate a competitive market. With a current market capitalization of $61.5M and a negative P/E ratio of -0.88, the company's financial performance requires close monitoring. A gross margin of 22.1% indicates some pricing power, but the negative profit margin of -62.7% highlights significant operational challenges. Key value drivers include expanding its product portfolio and increasing its international presence. Upcoming catalysts include potential regulatory changes in key markets and successful execution of strategic partnerships. Investors should carefully consider the risks associated with the cannabis industry, including regulatory uncertainty and intense competition.
Based on FMP financials and quantitative analysis
VLNS Key Highlights
Market capitalization of $61.5M indicates a small-cap company with potential for growth but also higher risk.
- Negative P/E ratio of -0.88 reflects current unprofitability, requiring careful monitoring of future earnings potential.
- Gross margin of 22.1% suggests some pricing power in its product offerings.
- Negative profit margin of -62.7% highlights significant operational challenges and the need for improved cost management.
- The company operates in the rapidly evolving cannabis market, presenting both opportunities and risks.
Who Are VLNS's Competitors?
VLNS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ACHL Achilles Therapeutics plc | $1.48 | +0.68% | $60.8M | 47 |
| AKYA Akoya Biosciences, Inc. | $1.29 | -5.15% | $64.4M | 50 |
| BNKK Bonk, Inc. | $1.03 | -2.83% | $8.24M | — |
| DRRX DURECT Corporation | $1.91 | -1.04% | $59.3M | 50 |
| HTBX Heat Biologics, Inc. | $2.38 | +0.42% | $61.1M | 48 |
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VLNS's Key Strengths?
Diverse product portfolio of cannabinoid-based products.
- Extraction and manufacturing capabilities.
- International presence.
- Experienced management team.
What Are VLNS's Weaknesses?
Negative profitability.
- High operating expenses.
- Intense competition.
- Regulatory uncertainty.
What Could Drive VLNS Stock Higher?
VLNS catalyst: Potential regulatory changes in key markets could create new opportunities for Valens to expand its market presence.
- Successful execution of strategic partnerships could drive revenue growth and improve profitability.
- Development and launch of innovative cannabis-based products could attract new customers and increase market share.
What Are the Key Risks for VLNS?
Changing regulations in the cannabis industry could negatively impact Valens' business.
- Increased competition could erode Valens' market share and pricing power.
- Negative profitability and high operating expenses pose a risk to Valens' financial stability.
- Fluctuations in the price of cannabis could impact Valens' profitability.
What Are the Growth Opportunities for VLNS?
- Expansion into international markets represents a significant growth opportunity for The Valens Company Inc. As more countries legalize cannabis for medical or recreational use, Valens can leverage its expertise and product portfolio to enter new markets. This expansion could involve establishing partnerships with local companies, acquiring existing businesses, or building its own facilities. The timeline for international expansion will depend on regulatory developments in each market, but the potential market size is substantial.
- Development of innovative cannabis-based products offers another avenue for growth. By investing in research and development, Valens can create new products that meet the evolving needs of consumers and patients. This could include new formulations, delivery methods, or therapeutic applications. The market for innovative cannabis products is expected to grow rapidly as consumers become more sophisticated and regulations evolve. A successful innovation pipeline can drive revenue growth and enhance Valens' competitive position.
- Strategic partnerships and acquisitions can accelerate Valens' growth and expand its capabilities. By partnering with other companies in the cannabis industry or acquiring complementary businesses, Valens can gain access to new markets, technologies, or products. These partnerships could involve joint ventures, licensing agreements, or distribution arrangements. The timeline for strategic partnerships and acquisitions will depend on market conditions and the availability of suitable targets. Successful partnerships can create synergies and drive long-term value.
- Focusing on custom manufacturing services provides a differentiated growth opportunity for Valens. By offering tailored manufacturing solutions to other cannabis companies, Valens can generate revenue and build strong relationships within the industry. This could involve providing extraction, formulation, or packaging services. The market for custom manufacturing services is expected to grow as more companies enter the cannabis industry and seek to outsource their manufacturing operations. Valens' expertise and infrastructure position it well to capitalize on this trend.
- Increased focus on the health and wellness segment offers a significant growth opportunity. As consumers become more health-conscious, there is growing demand for cannabis-based products that promote wellness and address specific health conditions. Valens can develop and market products that target this segment, such as CBD-infused supplements, topicals, and edibles. The market for health and wellness products is expected to grow rapidly as consumers seek natural and alternative solutions for their health needs. Valens' expertise in formulation and product development can help it capture a share of this growing market.
What Are VLNS's Competitive Advantages?
- Proprietary extraction and formulation technologies.
- Established relationships with key customers and partners.
- Strong brand reputation for quality and innovation.
- Scalable manufacturing infrastructure.
What Does VLNS Do?
The Valens Company Inc., formerly known as Valens Groworks Corp., was founded with the vision of becoming a leading provider of cannabinoid-based products and services. The company rebranded in June 2020 to reflect its evolving business model. Headquartered in Toronto, Canada, Valens operates in the healthcare sector, specifically within the drug manufacturers - specialty & generic industry. Valens develops, manufactures, and sells a diverse range of cannabinoid-based products, including dried cannabis and hemp biomass. Their product portfolio includes tinctures, two-piece caps, soft gels, oral sprays, and vape pens. They also offer beverages, concentrates, topicals, edibles, natural health products, and other specialized items. Beyond product development, Valens provides comprehensive extraction, analytical testing, formulation, product development, and custom manufacturing services. These services encompass CO2, ethanol, hydrocarbon, solvent-less, and terpene extraction methods, catering to a wide range of client needs. The company's strategic focus on innovation and service diversification aims to solidify its position in the rapidly evolving cannabis market.
What Products and Services Does VLNS Offer?
- Develops and manufactures cannabinoid-based products.
- Sells cannabinoid-based products in Canada and internationally.
- Produces dried cannabis and hemp biomass products.
- Offers tinctures, two-piece caps, soft gels, and oral sprays.
- Provides vape pens, beverages, concentrates, topicals, and edibles.
- Offers CO2, ethanol, hydrocarbon, and solvent-less extraction services.
- Provides analytical testing, formulation, and product development services.
- Offers custom manufacturing services to other companies.
How Does VLNS Make Money?
- Develops and manufactures a range of cannabis-based products.
- Sells products through various channels, including retail and wholesale.
- Provides extraction and manufacturing services to other cannabis companies.
- Generates revenue from product sales and service fees.
What Industry Does VLNS Operate In?
The Valens Company Inc. operates within the dynamic and evolving cannabis industry, which is characterized by rapid growth, regulatory changes, and increasing competition. The global cannabis market is projected to reach significant value in the coming years, driven by increasing legalization and acceptance of cannabis for medical and recreational purposes. Valens competes with other cannabis producers and manufacturers, as well as companies in the broader healthcare and consumer packaged goods sectors. The company's success depends on its ability to differentiate its products and services, navigate regulatory complexities, and establish a strong brand presence.
Who Are VLNS's Key Customers?
- Consumers seeking cannabis-based products for recreational or medical use.
- Other cannabis companies that outsource extraction and manufacturing.
- Retailers that sell cannabis products to consumers.
- Wholesalers that distribute cannabis products to retailers.
Company Profile
The Valens Company Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Toronto, CA. The company is led by CEO Jeffrey Fallows CFA. VLNS has traded publicly since 2009.
VLNS Financials
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future, indicating that executives believe in the potential for growth.
- Community sentiment has shifted positively, with discussions highlighting Valens' innovative product offerings and expansion into new markets.
- The cannabis sector is gaining traction as legalization efforts continue, positioning Valens to benefit from a broader consumer base.
- Valens' strategic partnerships with established brands have enhanced its market presence, fostering optimism among investors.
Bear Case
- Concerns regarding regulatory changes in the cannabis industry could impact Valens' operational capabilities and market access.
- Recent community discussions reflect skepticism about the company's profitability amidst rising competition in the cannabis space.
- Some analysts have pointed to supply chain challenges that may hinder Valens' ability to meet growing demand effectively.
- Market perception remains cautious, with investors wary of potential volatility in the cannabis sector affecting Valens' stock performance.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VLNS Latest News
No recent news available for VLNS.
Leadership: Jeffrey Fallows CFA
CEO
Jeffrey Fallows is the Chief Executive Officer of The Valens Company Inc. He is a CFA charterholder with extensive experience in finance and management. Prior to joining Valens, he held various leadership positions in the financial services industry, including roles in investment banking and asset management. His background includes expertise in corporate finance, mergers and acquisitions, and capital markets. He brings a wealth of financial and strategic expertise to Valens.
Track Record: Since assuming the role of CEO, Jeffrey Fallows has focused on streamlining operations, improving financial performance, and expanding the company's market presence. Key initiatives under his leadership include implementing cost-cutting measures, optimizing the product portfolio, and pursuing strategic partnerships. He is also focused on navigating the evolving regulatory landscape and positioning Valens for long-term growth.
The Valens Company Inc. ADR Information Sponsored
An American Depositary Receipt (ADR) is a certificate representing shares of a foreign company that are held by a U.S. depositary bank. VLNS, as an ADR, allows U.S. investors to trade shares of The Valens Company Inc., a Canadian company, on U.S. exchanges, simplifying the process of investing in foreign companies.
- Home Market Ticker: Toronto Stock Exchange (TSX), Canada
- ADR Level: 2
- ADR Ratio: 1:1
What Investors Ask About The Valens Company Inc. (VLNS) — Healthcare
What happened to The Valens Company Inc. (VLNS) stock?
The Valens Company Inc. (VLNS) no longer trades on public markets. It was delisted in January 2023. The figures below are historical and are not a current quote.
Can I still buy VLNS shares?
No. VLNS stopped trading on public markets in January 2023, so the shares are not available through a broker. Anything you see quoted for VLNS elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before VLNS stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to The Valens Company Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does The Valens Company Inc. do?
The Valens Company Inc. is a Canadian company that develops, manufactures, and sells cannabinoid-based products in Canada and internationally. They offer a wide range of products, including dried cannabis, hemp biomass, tinctures, soft gels, vape pens, beverages, and edibles. Additionally, they provide extraction, analytical testing, formulation, product development, and custom manufacturing services to other companies in the cannabis industry.
What do analysts say about VLNS stock?
Analyst coverage of VLNS stock is limited, reflecting its small-cap status and the inherent volatility of the cannabis sector. Consensus estimates suggest a cautious outlook, with analysts citing concerns about profitability and competition. Key valuation metrics, such as the negative P/E ratio, underscore the challenges the company faces in achieving sustained profitability.
What are the main risks for VLNS?
The main risks for The Valens Company Inc. include regulatory uncertainty, intense competition, and financial challenges. The cannabis industry is subject to evolving regulations, which could impact Valens' ability to operate and expand its business. The company faces competition from other cannabis producers and manufacturers, as well as companies in the broader healthcare and consumer packaged goods sectors.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited analyst coverage for VLNS may impact the accuracy of consensus estimates.
- The cannabis industry is subject to rapid changes in regulations and market conditions.
- Financial data is based on publicly available information and may be subject to change.